ArticlePatient related outcome measures2026

Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020-2024).

Charles Dharmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.